A 66-Year-Old Man With Gastric Carcinoma
Bassel El-Rayes, MD, an expert in oncology, discusses the DESTINY-Gastric01 trial of trastuzumab deruxtecan in HER2+ gastric cancer and comments on implications for second-line treatment and beyond.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Sacituzumab Govitecan Misses PFS in First-Line HR+/HER2– Metastatic Breast Cancer
2
Medication Burden Linked With Acute Care Use in ARSI-Treated Prostate Cancer
3
Exploring the IO Interface: Bridging Knowledge Gaps in Immunotoxicity Management
4
First-in-Human Data Support Izalontamab in Advanced Epithelial Tumors
5
